| Name | Title | Contact Details |
|---|---|---|
Jay Sivasailam |
Chief Growth Officer | Profile |
Dan Ness |
Vice President of Marketing, Public Relations, and Digital Transformation (interim) | Profile |
Troy Brice |
AVP Customer Service | Profile |
Margie Lindberg |
Vice President Marketing, Sales & Product Management | Profile |
Pleasant Radford |
Health Equity Officer | Profile |
Wintersun Chemical is a Ontario, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Manor at Market Square is a senior living community in Reading, PA that provides personal care assistance and 24 hour nursing care services.
Futrix is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
CareVet is a veterinary practice management group whose mission is to provide the very best care for pets through a holistic approach to medicine. We focus on five pillars of care: practice legacy, veterinarians, team, patients and community. ...